SCHEMBL13124665

SCHEMBL13124665

CC(C)NC(=O)C1CCCN1C(=O)C(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 6/20 0.46
REN P00797 4/20 0.46
KDM4E B2RXH2 1/20 0.46
F2 P00734 1/20 0.46
LMNA P02545 1/20 0.46
LTA4H P09960 1/20 0.46
MAPT P10636 1/20 0.46
PEPD P12955 1/20 0.46
ALOX15 P16050 1/20 0.46
PTGS1 P23219 1/20 0.46
HTR2A P28223 1/20 0.46
PTGS2 P35354 1/20 0.46
HRH1 P35367 1/20 0.46
THPO P40225 1/20 0.46
PMP22 Q01453 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ACE2 Q9BYF1 1/20 0.46
XIAP P98170 1/20 0.44
TSHR P16473 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16529713 0.84 ACE (0.44) ACERENKDM4EF2LMNA
SCHEMBL11440574 0.84 PREP (0.61) ACERENKDM4EF2LMNA
SCHEMBL24260126 0.81 MMP1 (0.47) ACERENKDM4EF2LMNA
SCHEMBL18897023 0.81 REN (0.48) ACERENKDM4EF2LMNA
SCHEMBL11516951 0.81 ACE (0.46) ACERENKDM4EF2LMNA
SCHEMBL13312891 0.80 ACE (0.50) ACERENKDM4EF2LMNA
SCHEMBL15851270 0.80 ACE (0.50) ACERENKDM4EF2LMNA
SCHEMBL17323620 0.80 ACE (0.68) ACERENKDM4EF2LMNA
SCHEMBL967588 0.80 ACE (0.68) ACERENKDM4EF2LMNA
SCHEMBL12015975 0.80 ACE (0.50) ACERENKDM4EF2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9278922-B2 Anti-viral compounds ABBVIE INC. (US) 2016-03-08 US disclosed
US-20100267634-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267634-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS ACE 256/4885REN 2184/4885KDM4E 2318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.